Видео ютуба по тегу Cd19-Directed Car-T

CD19-directed CAR-T in patients with R/R high-grade lymphoma
CD19-directed CAR-T in patients with R/R high-grade lymphoma
Clinical data for CD19-directed CAR T-cell products in ALL
Clinical data for CD19-directed CAR T-cell products in ALL
Outcomes of CD19-directed CAR T-cell therapy in five individuals with multiple sclerosis
Outcomes of CD19-directed CAR T-cell therapy in five individuals with multiple sclerosis
Dr. Park on CD19-Directed CAR T-Cell Therapy in Patients With ALL
Dr. Park on CD19-Directed CAR T-Cell Therapy in Patients With ALL
Impact of prior tafasitamab treatment on subsequent CD19-directed CAR-T therapy
Impact of prior tafasitamab treatment on subsequent CD19-directed CAR-T therapy
CD19-directed CAR T-cell therapy for patients with relapsed B-cell acute lymphocytic leukaemia
CD19-directed CAR T-cell therapy for patients with relapsed B-cell acute lymphocytic leukaemia
Overcoming antigen escape following CD19-directed CAR-T therapy
Overcoming antigen escape following CD19-directed CAR-T therapy
IFN-beta-1a for preventing toxicities after CD19-directed CAR T-cell therapy: a trial in progress
IFN-beta-1a for preventing toxicities after CD19-directed CAR T-cell therapy: a trial in progress
Risk factors for success or failure of CD19-directed CAR-T therapy in children with B-ALL
Risk factors for success or failure of CD19-directed CAR-T therapy in children with B-ALL
HD-CAR-1: 3rd-generation CD19-directed CAR-Ts for R/R CLL
HD-CAR-1: 3rd-generation CD19-directed CAR-Ts for R/R CLL
CAR T-Cell Therapy: How Does It Work?
CAR T-Cell Therapy: How Does It Work?
CD19 CAR T Cell Therapy for Pediatric ALL: The Seattle Children’s Experience
CD19 CAR T Cell Therapy for Pediatric ALL: The Seattle Children’s Experience
Efficacy of bispecific CD19/CD22 CAR T-cells in B-cell malignancies
Efficacy of bispecific CD19/CD22 CAR T-cells in B-cell malignancies
Determining which CD19-directed CAR-T product is best for each patient with LBCL
Determining which CD19-directed CAR-T product is best for each patient with LBCL
CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell ALL
CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell ALL
CD19 CAR T-cells for adults
CD19 CAR T-cells for adults
Late hematotoxicity of CD19-directed CAR-T in patients with LBCL
Late hematotoxicity of CD19-directed CAR-T in patients with LBCL
Checkpoint inhibitors augument CD19 CAR T-cell therapy in relapsed B-ALL
Checkpoint inhibitors augument CD19 CAR T-cell therapy in relapsed B-ALL
Лимфома: обзор Т-клеток с химерным антигенным рецептором (CAR)
Лимфома: обзор Т-клеток с химерным антигенным рецептором (CAR)
Durability & safety of CD22-directed CAR T-cells for patients with LBCL progressing on CD19 CAR-T
Durability & safety of CD22-directed CAR T-cells for patients with LBCL progressing on CD19 CAR-T